SCHEMBL4029309

SCHEMBL4029309

COc1cccc(C(=O)C(=O)c2ccncc2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.77
CES1 P23141 2/20 0.77
NPC1 O15118 3/20 0.62
KMT2A Q03164 2/20 0.60
CYP1A2 P05177 4/20 0.57
CYP1A1 P04798 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP1B1 Q16678 2/20 0.57
PARP1 P09874 1/20 0.57
ALDH1A1 P00352 5/20 0.54
RAB9A P51151 2/20 0.51
MAPT P10636 2/20 0.51
PKM P14618 1/20 0.51
XBP1 P17861 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
THRB P10828 1/20 0.51
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16108946 0.88 CES2 (0.68) CES2CES1NPC1KMT2ACYP1A2
SCHEMBL29610859 0.88 CES2 (1.00) CES2CES1NPC1KMT2APARP1
SCHEMBL2156482 0.88 CES2 (1.00) CES2CES1NPC1KMT2APARP1
SCHEMBL5216406 0.87 KMT2A (0.72) CES2CES1NPC1KMT2ACYP1A2
SCHEMBL9647505 0.86 CES2 (0.89) CES2CES1NPC1KMT2APARP1
SCHEMBL6605267 0.85 CES2 (0.59) CES2CES1NPC1KMT2ACYP1A2
SCHEMBL10921504 0.84 CES2 (0.72) CES2CES1KMT2ACYP1A2CYP1A1
SCHEMBL2479815 0.81 CES2 (0.54) CES2CES1NPC1KMT2ACYP1A2
SCHEMBL11815884 0.80 CES2 (0.76) CES2CES1KMT2ACYP1A2CYP1A1
SCHEMBL16108997 0.80 CES2 (0.57) CES2CES1NPC1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP disclosed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP disclosed
US-5717100-A Substituted imidazoles having anti-cancer and cytokine inhibitory activity MERCK & CO., INC. (US) 1998-02-10 US disclosed
WO-1997012876-A9 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY 1997-09-18 WO disclosed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO disclosed